# Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

> **NCT00949663** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 38 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Placebo
- **DRUG:** Glucose-dependent Insulinotropic Polypeptide (GIP)
- **DRUG:** Xenin-25
- **DRUG:** Glucose-dependent Insulinotropic Polypeptide plus Xenin-25

## Key facts

- **NCT ID:** NCT00949663
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949663, "Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00949663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*